| Species |
Cynomolgus |
| Protein Construction |
| His |
IL-33 (His109-Ile270)
Accession # A0A2K5W3I1-1 |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Human IL1RL1, hFc Tag captured on CM5 Chip via Protein A can bind IL-33, His, Cynomolgus in SPR assay (Biacore T200). Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
19.2 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 25-30 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Interleukin-33 (IL-33) is a cytokine belonging to the IL-1 family, playing a role in inflammatory, infectious and autoimmune diseases and expressed in the cellular nucleus in several tissues. High levels of IL-33 are expressed in epithelial barrier tissues and endothelial barriers. ST2 is a receptor for IL-33, expressed selectively on a subset of Th2 cells, mediating some of their functions. |
| Synonyms |
C9orf26 Z; DVS27; IL1F11; NF-HEV; NFEHEV; IL33; DV27; C9ORF26; RP11-575C20.2 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
